355 related articles for article (PubMed ID: 28749536)
1. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
2. Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies.
Hollenbeck BK; Oerline M; Kaufman SR; Caram MEV; Dusetzina SB; Ryan AM; Shahinian VB
Urology; 2021 Feb; 148():134-140. PubMed ID: 33075381
[TBL] [Abstract][Full Text] [Related]
3. Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data.
Sharma M; Vadhariya A; Johnson ML; Marcum ZA; Holmes HM
BMC Health Serv Res; 2018 Apr; 18(1):236. PubMed ID: 29609611
[TBL] [Abstract][Full Text] [Related]
4. Adoption of Abiraterone and Enzalutamide by Urologists.
Caram MEV; Kaufman SR; Modi PK; Herrel L; Oerline M; Ross R; Skolarus TA; Hollenbeck BK; Shahinian V
Urology; 2019 Sep; 131():176-183. PubMed ID: 31136769
[TBL] [Abstract][Full Text] [Related]
5. The Association between Industry Payments and Brand-Name Prescriptions in Otolaryngologists.
Morse E; Hanna J; Mehra S
Otolaryngol Head Neck Surg; 2019 Oct; 161(4):605-612. PubMed ID: 31547772
[TBL] [Abstract][Full Text] [Related]
6. Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
Caram MEV; Borza T; Min HS; Griggs JJ; Miller DC; Hollenbeck BK; Mukherjee B; Skolarus TA
J Oncol Pract; 2017 Aug; 13(8):e694-e702. PubMed ID: 28628393
[TBL] [Abstract][Full Text] [Related]
7. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2018 Sep; 159(3):442-448. PubMed ID: 29865931
[TBL] [Abstract][Full Text] [Related]
8. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
9. Association between industry payments for opioid products and physicians' prescription of opioids: observational study with propensity-score matching.
Inoue K; Figueroa JF; Orav EJ; Tsugawa Y
J Epidemiol Community Health; 2020 Aug; 74(8):647-654. PubMed ID: 32350126
[TBL] [Abstract][Full Text] [Related]
10. Industry Payments to Physician Specialists Who Prescribe Repository Corticotropin.
Hartung DM; Johnston K; Cohen DM; Nguyen T; Deodhar A; Bourdette DN
JAMA Netw Open; 2018 Jun; 1(2):e180482. PubMed ID: 30646086
[TBL] [Abstract][Full Text] [Related]
11. Association between industry payments and prescriptions of long-acting insulin: An observational study with propensity score matching.
Inoue K; Tsugawa Y; Mangione CM; Duru OK
PLoS Med; 2021 Jun; 18(6):e1003645. PubMed ID: 34061852
[TBL] [Abstract][Full Text] [Related]
12. Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.
Lai LY; Oerline MK; Kaufman SR; Herrel LA; Skolarus TA; Dusetzina SB; Ellimoottil C; Shahinian VB; Hollenbeck BK; Caram MEV
Urology; 2022 Mar; 161():50-58. PubMed ID: 34861316
[TBL] [Abstract][Full Text] [Related]
13. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2019 Jan; 160(1):70-76. PubMed ID: 30325706
[TBL] [Abstract][Full Text] [Related]
14. Disclosure of industry payments to prescribers: industry payments might be a factor impacting generic drug prescribing.
Qian J; Hansen RA; Surry D; Howard J; Kiptanui Z; Harris I
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):819-826. PubMed ID: 28485111
[TBL] [Abstract][Full Text] [Related]
15. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.
Zezza MA; Bachhuber MA
PLoS One; 2018; 13(12):e0209383. PubMed ID: 30566426
[TBL] [Abstract][Full Text] [Related]
16. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
Yeh JS; Franklin JM; Avorn J; Landon J; Kesselheim AS
JAMA Intern Med; 2016 Jun; 176(6):763-8. PubMed ID: 27159336
[TBL] [Abstract][Full Text] [Related]
17. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology.
Duarte-García A; Crowson CS; McCoy RG; Herrin J; Lam V; Putman MS; Ross JS; Matteson EL; Shah ND
Mayo Clin Proc; 2022 Feb; 97(2):250-260. PubMed ID: 35120693
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
DeJong C; Aguilar T; Tseng CW; Lin GA; Boscardin WJ; Dudley RA
JAMA Intern Med; 2016 Aug; 176(8):1114-1122. PubMed ID: 27322350
[TBL] [Abstract][Full Text] [Related]
19. The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab.
Bandari J; Turner RM; Jacobs BL; Canes D; Moinzadeh A; Davies BJ
Urol Pract; 2017 Jan; 4(1):14-20. PubMed ID: 28149927
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Industry-Dermatologist Financial Relationship: Insight From the Open Payment Data.
Feng H; Wu P; Leger M
JAMA Dermatol; 2016 Dec; 152(12):1307-1313. PubMed ID: 27706478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
